Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

PHASE3CompletedINTERVENTIONAL
Enrollment

2,038

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

October 12, 2021

Study Completion Date

October 12, 2021

Conditions
Infection, Respiratory Tract
Interventions
BIOLOGICAL

VPM1002

The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).

BIOLOGICAL

Placebo

The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).

Trial Locations (12)

10629

emovis GmbH, Berlin

10787

Klinische Forschung Berlin GbR, Berlin

20253

Klinische Forschung Hamburg GmbH, Hamburg

30159

Klinische Forschung Hannover Mitte GmbH, Hanover

30625

Medizinische Hochschule Hannover, Hanover

45355

Medizentrum Essen Borbeck, Essen

55128

BAG Dres. med. Quist PartG, Mainz

60389

Studienzentrum Dr. Keller, Frankfurt am Main

70178

Hautarztpraxis Dres. Leitz & Kollegen, Stuttgart

99084

SocraTec R&D GmbH, Erfurt

03050

MECS Cottbus GmbH, Cottbus

04103

SIBAmed GmbH & Co. KG, Leipzig

Sponsors
All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

lead

Serum Life Science Europe GmbH

INDUSTRY